Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors – Enduring Webcast

Description

Program Description

---

This webcast is intended to improve care of patients with HR+ and HER2- metastatic breast cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

---

This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients with HR+ and HER2- metastatic breast cancer.

Commercial Supporter

---

Supported by Novartis Pharmaceuticals Corporation